NPCE NeuroPace Inc

Price (delayed)

$7.64

Market cap

$219.79M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.18

Enterprise value

$279.75M

Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating ...

Highlights
NeuroPace's gross profit has increased by 48% YoY and by 6% from the previous quarter
NPCE's revenue is up by 42% year-on-year and by 6% since the previous quarter
NeuroPace's quick ratio has decreased by 31% YoY but it has increased by 11% QoQ
NPCE's equity is down by 48% year-on-year and by 31% since the previous quarter
The debt has increased by 3.9% YoY

Key stats

What are the main financial stats of NPCE
Market
Shares outstanding
28.77M
Market cap
$219.79M
Enterprise value
$279.75M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
15.1
Price to sales (P/S)
3.13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.05
Earnings
Revenue
$69.07M
EBIT
-$22.7M
EBITDA
-$21.06M
Free cash flow
-$17.68M
Per share
EPS
-$1.18
Free cash flow per share
-$0.62
Book value per share
$0.51
Revenue per share
$2.44
TBVPS
$3.49
Balance sheet
Total assets
$98.85M
Total liabilities
$84.51M
Debt
$73.09M
Equity
$14.34M
Working capital
$71.14M
Liquidity
Debt to equity
5.1
Current ratio
6.43
Quick ratio
5.39
Net debt/EBITDA
-2.85
Margins
EBITDA margin
-30.5%
Gross margin
74%
Net margin
-45.6%
Operating margin
-38.2%
Efficiency
Return on assets
-30.9%
Return on equity
-173.6%
Return on invested capital
-15.3%
Return on capital employed
-26.5%
Return on sales
-32.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NPCE stock price

How has the NeuroPace stock price performed over time
Intraday
2.69%
1 week
12.19%
1 month
18.27%
1 year
82.34%
YTD
-25.9%
QTD
1.06%

Financial performance

How have NeuroPace's revenue and profit performed over time
Revenue
$69.07M
Gross profit
$51.09M
Operating income
-$26.4M
Net income
-$31.51M
Gross margin
74%
Net margin
-45.6%
NeuroPace's operating margin has soared by 53% YoY and by 8% from the previous quarter
The net margin has soared by 52% YoY and by 10% from the previous quarter
NeuroPace's gross profit has increased by 48% YoY and by 6% from the previous quarter
NPCE's revenue is up by 42% year-on-year and by 6% since the previous quarter

Growth

What is NeuroPace's growth rate over time

Valuation

What is NeuroPace stock price valuation
P/E
N/A
P/B
15.1
P/S
3.13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.05
NeuroPace's EPS has increased by 36% YoY and by 7% QoQ
NPCE's equity is down by 48% year-on-year and by 31% since the previous quarter
The price to book (P/B) is 2% lower than the last 4 quarters average of 15.0
NPCE's revenue is up by 42% year-on-year and by 6% since the previous quarter
NPCE's price to sales (P/S) is 22% less than its last 4 quarters average of 3.9

Efficiency

How efficient is NeuroPace business performance
NeuroPace's return on sales has surged by 58% YoY and by 12% QoQ
NeuroPace's ROE has decreased by 50% YoY and by 13% from the previous quarter
NPCE's ROIC is up by 34% year-on-year and by 5% since the previous quarter
The company's return on assets rose by 23% YoY and by 2.5% QoQ

Dividends

What is NPCE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NPCE.

Financial health

How did NeuroPace financials performed over time
NPCE's total assets is 17% higher than its total liabilities
NeuroPace's quick ratio has decreased by 31% YoY but it has increased by 11% QoQ
The company's current ratio fell by 30% YoY but it rose by 13% QoQ
NeuroPace's debt to equity has surged by 99% YoY and by 45% QoQ
NPCE's equity is down by 48% year-on-year and by 31% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.